Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Thu., Apr. 25, 1:06 AM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
| This Slide: #71 of 100 |
Slide #71. Aratana Therapeutics, Inc — Vet Therapeutics, Inc.
Acquirer:
Aratana Therapeutics, Inc (PETX)
Acquiree:
Vet Therapeutics, Inc.
Details:
Aratana Therapeutics, Inc. (Nasdaq: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets (pet therapeutics), today announced that it has entered into a merger agreement providing for the strategic acquisition of Vet Therapeutics, Inc., a San Diego-based company with a proprietary antibody-based biologics platform. Under the agreement, Aratana plans to continue to advance the pipeline of high value biologic drugs, including its lymphoma franchise. Importantly, the acquisition of Vet Therapeutics is expected to significantly accelerate Aratana's pathway toward becoming a commercial-stage pet therapeutics company.
Aratana Therapeutics is a pet therapeutics company that licenses, develops and commercializes therapeutics for dogs and cats. At Dec 31 2017, Co.'s portfolio included multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and molecule biologics. Co. has three U.S. Food and Drug Administration approved therapeutics: GALLIPRANT® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE® (capromorelin oral solution) for appetite stimulation in dogs; and NOCITA® (bupivacaine liposome injectable suspension) as a local post-operative analgesia for cranial cruciate ligament surgery in dogs.
Open the PETX Page at The Online Investor »
|
|||||||||
Open the PETX Page at The Online Investor (in a new window) »
 Free PETX Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
|
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
